Ligand director Jason Aryeh sells 2,111 shares
The director’s direct sales are reported separately from 8,000 shares held indirectly by funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ligand Pharmaceuticals Inc. (LGND) director Jason Aryeh reported six direct sales of 2,111 common shares: five transactions on October 30, 2026, at $317.7400, $318.2300, $320.2400, $320.4172 and $320.4900 per share, and 700 shares on November 2 at a weighted-average $320.4261 per share. The November 2 shares were sold in multiple transactions at prices ranging from $320.39 to $320.49. The report also lists 8,000 shares held indirectly by funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates; Aryeh is identified as general partner of JALAA Equities and a partner of JLV Investments.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F2 | 700 | $320.4261 | $224K |
| Sale | Common Stock F1 | 50 | $317.74 | $16K |
| Sale | Common Stock | 50 | $318.23 | $16K |
| Sale | Common Stock | 52 | $320.24 | $17K |
| Sale | Common Stock | 1,209 | $320.4172 | $387K |
| Sale | Common Stock | 50 | $320.49 | $16K |
| Holding | Common Stock F3 | -- | -- | -- |
Footnotes (3)
- F1. Reflects adjustments to the holdings reported on the Reporting Persons Form 4 filed on June 12, 2026: (i) the Reporting Person transferred 5,000 shares held by JALAA Equities, LP to his direct ownership. The transfer effected only a change in the form of the Reporting Persons beneficial ownership and is exempt from Section 16 pursuant to Rule 16a-13. Accordingly, the number of shares reported herein as directly owned has been increased by 5,000 shares and the number of shares reported herein as indirectly owned has been decreased by 5,000 shares; and (ii) the number of shares reported herein as directly owned has been further increased by 3,289 shares, consisting of 1,209 shares issued upon the vesting on June 5, 2026 of restricted stock units granted on June 6, 2025, and 2,080 shares held in the Reporting Persons brokerage account, which were inadvertently omitted from the previously reported total.
- F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $320.39 to $320.49. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. These shares are held by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the Funds). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
Key Figures
Key Terms
weighted-average price financial
Rule 16a-13 regulatory
Rule 16a-1 regulatory
restricted stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.